Saturday, Bristol Myers Squibb & Co (NYSE:BMY) released interim long-term safety, tolerability, and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.  At the time of the data cutoff of August 18, 2023, the interim pooled data analysis included 718 patients who received at least one dose of KarXT, with 134 patients having completed one year of treatment. In the pooled analysis, KarXT demonstrated a favorable impact on weight and long-term metabolic profile. Most patients experienced stability or improvements in key metabolic parameters over 52 weeks of treatment.  The majority of patients (65%) experienced an overall reduction in weight, with more patients (18%) experiencing potentially clinically significant decreases in weight vs. 4% ...